Esperion Therapeutics (ESPR) Revenue & Revenue Breakdown
Esperion Therapeutics Revenue Highlights
Latest Revenue (Y)
$116.33M
Latest Revenue (Q)
$73.83M
Main Segment (Y)
Product
Esperion Therapeutics Revenue by Period
Esperion Therapeutics Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $116.33M | 54.14% |
| 2022-12-31 | $75.47M | -3.79% |
| 2021-12-31 | $78.45M | -65.52% |
| 2020-12-31 | $227.55M | 53.37% |
| 2019-12-31 | $148.36M | -19.57% |
| 2018-12-31 | $184.47M | 100.00% |
| 2017-12-31 | - | 100.00% |
| 2016-12-31 | - | 100.00% |
| 2015-12-31 | - | 100.00% |
| 2014-12-31 | - | -100.00% |
| 2013-12-31 | $4.98B | 100.00% |
| 2012-12-31 | - | 100.00% |
| 2011-12-31 | - | 100.00% |
| 2002-12-31 | - | 100.00% |
| 2001-12-31 | - | -100.00% |
| 2000-12-31 | $2.00K | 100.00% |
| 1999-12-31 | - | - |
Esperion Therapeutics generated $116.33M in revenue during NA 2023, up 54.14% compared to the previous quarter, and up 63.06% compared to the same period a year ago.
Esperion Therapeutics Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | $73.83M | -46.39% |
| 2024-03-31 | $137.74M | 327.09% |
| 2023-12-31 | $32.25M | -5.06% |
| 2023-09-30 | $33.97M | 31.73% |
| 2023-06-30 | $25.79M | 5.99% |
| 2023-03-31 | $24.33M | 29.29% |
| 2022-12-31 | $18.82M | -0.85% |
| 2022-09-30 | $18.98M | 0.74% |
| 2022-06-30 | $18.84M | 0.03% |
| 2022-03-31 | $18.84M | 22.30% |
| 2021-12-31 | $15.40M | 6.88% |
| 2021-09-30 | $14.41M | -64.56% |
| 2021-06-30 | $40.66M | 409.64% |
| 2021-03-31 | $7.98M | -17.22% |
| 2020-12-31 | $9.64M | 151.45% |
| 2020-09-30 | $3.83M | -98.19% |
| 2020-06-30 | $212.24M | 11434.57% |
| 2020-03-31 | $1.84M | 87.37% |
| 2019-12-31 | $982.00K | 0.10% |
| 2019-09-30 | $981.00K | -0.10% |
| 2019-06-30 | $982.00K | -99.32% |
| 2019-03-31 | $145.42M | -21.17% |
| 2018-12-31 | $184.47M | 100.00% |
| 2018-09-30 | - | 100.00% |
| 2018-06-30 | - | 100.00% |
| 2018-03-31 | - | 100.00% |
| 2017-12-31 | - | 100.00% |
| 2017-09-30 | - | 100.00% |
| 2017-06-30 | - | 100.00% |
| 2017-03-31 | - | 100.00% |
| 2016-12-31 | - | 100.00% |
| 2016-09-30 | - | 100.00% |
| 2016-06-30 | - | 100.00% |
| 2016-03-31 | - | 100.00% |
| 2015-12-31 | - | 100.00% |
| 2015-09-30 | - | 100.00% |
| 2015-06-30 | - | 100.00% |
| 2015-03-31 | - | 100.00% |
| 2014-12-31 | - | 100.00% |
| 2014-09-30 | - | 100.00% |
| 2014-06-30 | - | 100.00% |
| 2014-03-31 | - | 100.00% |
| 2013-12-31 | - | 100.00% |
| 2013-09-30 | - | 100.00% |
| 2013-06-30 | - | 100.00% |
| 2013-03-31 | - | 100.00% |
| 2012-12-31 | - | 100.00% |
| 2012-09-30 | - | 100.00% |
| 2012-06-30 | - | 100.00% |
| 2012-03-31 | - | 100.00% |
| 2003-09-30 | - | 100.00% |
| 2003-06-30 | - | 100.00% |
| 2003-03-31 | - | 100.00% |
| 2002-12-31 | - | 100.00% |
| 2002-09-30 | - | 100.00% |
| 2002-06-30 | - | 100.00% |
| 2002-03-31 | - | 100.00% |
| 2001-12-31 | - | 100.00% |
| 2001-09-30 | - | -100.00% |
| 2001-06-30 | $1.00K | - |
| 2001-03-31 | $1.00K | - |
| 2000-12-31 | $1.00K | - |
| 2000-09-30 | $1.00K | - |
| 2000-06-30 | $1.00K | 100.00% |
| 2000-03-31 | - | - |
Esperion Therapeutics generated $73.83M in revenue during Q2 2024, up -46.39% compared to the previous quarter, and up 303.48% compared to the same period a year ago.
Esperion Therapeutics Revenue Breakdown
Esperion Therapeutics Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 23 | Dec 22 | Dec 21 | Dec 20 | Dec 19 |
|---|---|---|---|---|---|
| Product | $78.33M | $55.86M | - | - | - |
| Collaboration Revenue | $38.00M | $19.61M | $38.40M | $214.58M | - |
| Royalty Revenue From DSE | - | - | $9.90M | - | - |
| Ongoing Regulatory And Development Activities Revenue | - | - | - | $1.60M | $4.00M |
| Product Sales Bulk Tablets And Royalty Revenue Of Nilemdo And Nustendi | - | - | - | $2.80M | - |
| Milestone Marketing Authorization Approval Nustendi | - | - | - | $150.00M | - |
| License For Intellectual Property Revenue | - | - | - | - | $144.40M |
Esperion Therapeutics's latest annual revenue breakdown by segment (product or service), as of Dec 23: Product (67.34%), and Collaboration Revenue (32.66%).
Quarterly Revenue by Product
| Product/Service | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product | $24.76M | $20.76M | $20.25M | $20.29M | $17.03M | $14.97M | $12.19M | $8.17M | - | - | - | - | - | - | - | - | - | - | - | - |
| Collaboration Revenue | $112.98M | $11.49M | $13.72M | $5.49M | $7.30M | $3.85M | $5.02M | $5.26M | $5.48M | $3.21M | $3.51M | $30.05M | $1.63M | $1.47M | $502.00K | $211.63M | $982.00K | - | - | - |
| Royalty Revenue And Product Sales Bulk Tablets | - | - | - | - | - | - | $4.40M | $5.00M | $5.30M | $3.30M | - | - | - | - | - | - | - | - | - | - |
| Royalty Revenue And Product Sales Bulk Tablets Nilemdo And Nustendi | - | - | - | - | - | - | - | - | - | - | - | $2.00M | - | - | - | - | - | - | - | - |
| Product Sales Bulk Tablets Nilemdo And Nustendi | - | - | - | - | - | - | - | - | - | - | - | - | $1.60M | $500.00K | $1.00M | - | - | - | - | - |
| Milestone Marketing Authorization Approval Nustendi | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $150.00M | - | - | - | - |
| Regulatory Performance Obligations | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $700.00K | - | - | - | - |
| Ongoing Regulatory Activities Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $1.00M | - | - | - |
| Ongoing Regulatory And Development Activities Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $1.00M | $1.00M | $1.00M |
| License For Intellectual Property Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Esperion Therapeutics's latest quarterly revenue breakdown by segment (product or service), as of Mar 24: Collaboration Revenue (82.03%), and Product (17.97%).
Esperion Therapeutics Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| ELAN | Elanco Animal Health | $4.42B | $1.21B |
| CTLT | Catalent | $4.38B | $1.07B |
| NBIX | Neurocrine Biosciences | $1.89B | $590.20M |
| ALKS | Alkermes | $1.66B | $399.13M |
| PBH | Prestige Consumer Healthcare | $1.13B | $267.14M |
| PAHC | Phibro Animal Health | $977.89M | $263.22M |
| PCRX | Pacira BioSciences | $674.98M | $178.02M |
| COLL | Collegium Pharmaceutical | $566.77M | $144.92M |
| ANIP | ANI Pharmaceuticals | $486.82M | $138.04M |
| ITCI | Intra-Cellular Therapies | $462.18M | $144.87M |
| IRWD | Ironwood Pharmaceuticals | $442.74M | $94.40M |
| EGRX | Eagle Pharmaceuticals | $316.61M | $64.65M |
| DCPH | Deciphera Pharmaceuticals | $163.36M | $45.00M |
| KMDA | Kamada | $144.76M | $37.40M |
| SIGA | SIGA | $139.92M | $21.81M |
| LFCR | Lifecore Biomedical | $128.26M | $35.70M |
| ESPR | Esperion Therapeutics | $116.33M | $73.83M |
| RMTI | Rockwell Medical | $83.61M | $22.68M |
| AVDL | Avadel Pharmaceuticals | $27.96M | $41.50M |
| AGRX | Agile Therapeutics | $19.59M | $5.58M |
ESPR Revenue FAQ
What is Esperion Therapeutics’s yearly revenue?
Esperion Therapeutics's yearly revenue for 2023 was $116.33M, representing an increase of 54.14% compared to 2022. The company's yearly revenue for 2022 was $75.48M, representing a decrease of -3.79% compared to 2021. ESPR's yearly revenue for 2021 was $78.45M, representing a decrease of -65.52% compared to 2020.
What is Esperion Therapeutics’s quarterly revenue?
Esperion Therapeutics's quarterly revenue for Q2 2024 was $73.83M, a -46.39% decrease from the previous quarter (Q1 2024), and a 186.33% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $137.74M, a 327.09% increase from the previous quarter (Q4 2023), and a 466.14% increase year-over-year (Q1 2023). ESPR's quarterly revenue for Q4 2023 was $32.25M, a -5.06% decrease from the previous quarter (Q3 2023), and a 71.38% increase year-over-year (Q4 2022).
What is Esperion Therapeutics’s revenue growth rate?
Esperion Therapeutics's revenue growth rate for the last 3 years (2021-2023) was 48.30%, and for the last 5 years (2019-2023) was -21.59%.
What are Esperion Therapeutics’s revenue streams?
Esperion Therapeutics's revenue streams in c 23 are Product, and Collaboration Revenue. Product generated $78.34M in revenue, accounting 67.34% of the company's total revenue, up 40.23% year-over-year. Collaboration Revenue generated $38M in revenue, accounting 32.66% of the company's total revenue, up 93.75% year-over-year.
What is Esperion Therapeutics’s main source of revenue?
For the fiscal year ending Dec 23, the largest source of revenue of Esperion Therapeutics was Product. This segment made a revenue of $78.34M, representing 67.34% of the company's total revenue.